Juvenon Inc announced the initiation of a clinical trial to evaluate the effect of Juvenon Energy Formula on cardiovascular disease patients. The trial, funded by a grant from the National Institutes of Health (NIH), is being conducted at the Whitaker Cardiovascular Institute, a unit of Boston University School of Medicine. It is designed to assess the effects of Juvenon Energy Formula on endothelial function in elderly patients with coronary artery disease. Dysfunction of the endothelial cells, the cells that line the blood vessels, contributes to the progression of cardiovascular disease and is recognized as an important surrogate for cardiovascular disease risk.
"Juvenon Energy Formula has been shown in preclinical trials to reduce oxidative damage to the mitochondria, thereby improving cellular function," said Joseph Vita, Professor of Medicine, Boston University Medical Center, and principal investigator. "Recent research indicates that oxidative damage to the cells in the vascular system contributes to the risk of heart disease. We hypothesize that an intervention designed to improve cellular function, like Juvenon Energy Formula, will have a beneficial effect on endothelial dysfunction in elderly patients with cardiovascular disease."
The Juvenon Energy Formula dietary supplement consists of two mitochondrial-activating components that improve energy levels, reduce signs of aging in revitalized cells and increase burning of fat for energy. This novel supplement was developed at the University of California, Berkeley by renowned scientist Bruce Ames, a winner of the National Medal of Science and other international honors, and Tory Hagen, a researcher at the Linus Pauling Institute at Oregon State University.
This 40-person trial will determine the effect of Juvenon Energy Formula on the endothelial cells that line the blood vessels. The trial is designed to determine if an intervention to improve mitochondrial function (Juvenon Energy Formula) will have a beneficial effect on endothelial function. The study will test the blood vessels' ability to respond to changes in blood flow by dilating (expanding). Loss of normal dilator function reflects a loss of normal endothelial function and is associated with an increased risk of heart attack or stroke. The trial is designed as a double-blind, randomized, placebo-controlled crossover study and will enroll patients from 55 to 95 years old with proven coronary artery disease.